What is gastroparesis?

Delayed gastric emptying severe enough to cause symptoms without mechanical obstruction — nausea, vomiting, early fullness and bloating.

Why do GLP-1 drugs cause it?

Delaying gastric emptying is part of how they work. The complication is that intended mechanism taken to an extreme.

What does dose escalation have to do with it?

The emptying delay is largest when a dose is new and attenuates with continued exposure, so rapid escalation reintroduces the strongest effect repeatedly.

GLP-1 & Incretin Science

When the Intended Effect Goes Too Far

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Olubodun and colleagues published a systematic review of gastroparesis induced by GLP-1 receptor agonists in PLoS One in 2026, describing clinical features, diagnosis, management and outcomes, and characterising it as an under-recognised but clinically important complication.

Key facts

Systematic review: Olubodun 2026 (PMID 42594084)
Journal: PLoS One
Described as: Under-recognised but clinically important
Covers: Features, diagnosis, management, outcomes
Case report: Singhal 2025 (PMID 41054677)
Implicated factor: Rapid dose escalation

What gastroparesis is

Delayed gastric emptying severe enough to cause symptoms in the absence of mechanical obstruction — nausea, vomiting, early fullness, bloating and sometimes weight loss. It is defined by the combination of measurably slow emptying and symptoms attributable to it, not by slow emptying alone.

Why this class produces it

Because delaying gastric emptying is part of how these drugs work. Prolonging fullness and blunting the post-meal glucose rise are intended effects, and they are produced by the same slowing that, taken far enough, becomes the condition. The complication is the mechanism at an extreme rather than an unrelated toxicity.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why that makes the boundary hard to draw

There is no clean line between intended effect and complication when both are the same physiological change. Reduced appetite and early fullness are the point of the treatment and are also gastroparesis symptoms. Distinguishing them depends on severity, persistence and whether the person can maintain adequate intake — which is a clinical judgement rather than a measurement.

The dose escalation observation

Singhal and colleagues reported a case in Cureus in 2025 framed explicitly around the dangers of rapid dose escalation. That is mechanistically coherent: the emptying delay is largest when a dose is new and attenuates with continued exposure, so moving quickly through doses reintroduces the strongest effect repeatedly rather than allowing adaptation.

Why a systematic review matters for a complication like this

Case reports establish that something happens; they cannot say how often or in whom. Pooling them systematically produces a description of typical features, how the diagnosis is reached and what happens subsequently. For an under-recognised complication that is the necessary first step — before frequency can be estimated, the entity has to be characterised.

What this concerns

Licensed medicines prescribed and monitored clinically, and published clinical literature about them. Nothing supplied on this site is a GLP-1 receptor agonist, affects gastric emptying, or has any bearing on the care of any person.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What is gastroparesis?: Delayed gastric emptying severe enough to cause symptoms without mechanical obstruction — nausea, vomiting, early fullness and bloating.
Why do GLP-1 drugs cause it?: Delaying gastric emptying is part of how they work. The complication is that intended mechanism taken to an extreme.
What does dose escalation have to do with it?: The emptying delay is largest when a dose is new and attenuates with continued exposure, so rapid escalation reintroduces the strongest effect repeatedly.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum